CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission
City of Hope Medical Center
Abstract
This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of B-cell acute lymphoblastic leukemia. Phase: PHASE1 Status: ACTIVE_NOT_RECRUITING Conditions: B Acute Lymphoblastic Leukemia Interventions: Autologous Anti-CD19 CAR-expressing T Lymphocytes; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Cyclophosphamide; Fludarabine; Leukapheresis; Questionnaire Administration